logo

Nektar Therapeutics (NKTR)



Trade NKTR now with
  Date
  Headline
10/7/2019 9:03:08 AM Nektar Initiates 2 Studies Of Novel T Regulatory Cell Stimulator NKTR-358 In Patients With Psoriasis, Atopic Dermatitis
10/1/2019 8:03:34 AM Nektar Therapeutics Promotes Gil Labrucherie To COO In Addition To His Role As CFO
9/26/2019 7:02:17 AM Nektar Therapeutics Reports Presentation Of New Clinical Data For Bempegaldesleukin With Nivolumab
8/8/2019 4:25:20 PM Nektar Therapeutics Q2 Loss/share $0.63 Vs. Profit $5.33 Year Ago
8/1/2019 7:24:38 AM Nektar, Bristol-Myers Announce FDA Breakthrough Therapy Designation For NKTR-214 In Combination With Opdivo
6/13/2019 6:47:50 AM Nektar Therapeutics Announces Results From Phase 1a Study Of NKTR-358 At Annual European Congress Of Rheumatology
6/1/2019 12:37:57 PM Nektar Therapeutics Presents Biomarker And Clinical Data From PIVOT-02 Phase 2 Study Of Bempegaldesleukin With Nivolumab
5/23/2019 8:07:40 AM Nektar Announces The Launch Of Inheris Biopharma
5/23/2019 8:00:00 AM Nektar Announces the Launch of Inheris Biopharma, Inc. (Press Release)
5/8/2019 4:12:29 PM Nektar Therapeutics Q1 Loss/share $0.68 Vs. Loss $0.60 Year Ago
2/28/2019 4:12:55 PM Nektar Therapeutics Q4 Loss/share $0.57 Vs. Loss $0.21 Year Ago
1/3/2019 7:01:26 AM ImaginAb Enters Non-exclusive License And Clinical Trial Collaboration With Nektar Therapeutics
  
 
>